logo
Plus   Neg
Share
Email

FDA Approves Aimmune's (AIMT) Palforzia, Stock Up 17% In After-Hours

The FDA has approved Aimmune Therapeutics Inc.'s (AIMT) Palforzia for the treatment of peanut allergy in patients aged 4 through 17 years.

Up-dosing and maintenance may be continued in patients 4 years of age and older, and the drug is to be used in conjunction with a peanut-avoidant diet, the Company noted.

Palforzia is not only the first approved therapy for peanut allergy but is also the first approved therapy for any food allergy. It is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

AIMT closed Friday's trading at $31.05, down 2.91%. In after-hours, the stock was up 16.88% to $36.29.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT